KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $570.0 million.

  • Abbott Laboratories' Net Cash Flow rose 654.21% to $570.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.0 million, marking a year-over-year decrease of 10346.48%. This contributed to the annual value of $816.0 million for FY2024, which is 12753.97% up from last year.
  • Abbott Laboratories' Net Cash Flow amounted to $570.0 million in Q3 2025, which was up 654.21% from $368.0 million recorded in Q2 2025.
  • Over the past 5 years, Abbott Laboratories' Net Cash Flow peaked at $1.3 billion during Q2 2022, and registered a low of -$2.1 billion during Q1 2022.
  • Its 5-year average for Net Cash Flow is $48.4 million, with a median of $368.0 million in 2025.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 40217.92% in 2021, then tumbled by 26971.15% in 2022.
  • Abbott Laboratories' Net Cash Flow (Quarter) stood at $510.0 million in 2021, then plummeted by 53.53% to $237.0 million in 2022, then plummeted by 31.65% to $162.0 million in 2023, then dropped by 12.96% to $141.0 million in 2024, then skyrocketed by 304.26% to $570.0 million in 2025.
  • Its Net Cash Flow was $570.0 million in Q3 2025, compared to $368.0 million in Q2 2025 and -$1.1 billion in Q1 2025.